VRDN

Business Context and Reporting Period

Company: Viridian Therapeutics, Inc. (VRDN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Viridian is a biopharmaceutical company focused on developing best-in-class medicines for serious and rare diseases, primarily targeting Thyroid Eye Disease (TED) and autoimmune disorders via FcRn inhibitors. The company has no approved products and generates no revenue from product sales.

Key Financial Metrics

Note: Revenue consists entirely of collaboration revenue from the Zenas BioPharma agreement. The company reported $29.1 million in net other income in 2024, primarily driven by $31.6 million in interest income.

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses rose by $78.5 million (49%) year-over-year. This was driven by a $59.5 million increase in direct costs for the TED portfolio (veligrotug and VRDN-003) and a $12.0 million increase for the FcRn inhibitor portfolio.
• Decreased G&A Expenses: G&A expenses declined by $33.9 million (36%), primarily due to a $27.2 million reduction in severance costs and share-based compensation related to former executive officers.
• Capital Raising: The company raised approximately $451.7 million in net proceeds during 2024 through public offerings and an At-The-Market (ATM) agreement, significantly bolstering its cash position.
• Financial Restatement: The company corrected an immaterial error regarding the calculation of net loss per share for prior periods (2022 and 2023) to properly allocate losses to Series A and Series B Convertible Preferred Stock using the two-class method.

Guidance, Outlook, and Management Commentary

Clinical Milestones and Pipeline

• Veligrotug (TED): Announced positive topline data for Phase 3 trials THRIVE (active TED) and THRIVE-2 (chronic TED) in late 2024. Both trials met primary and secondary endpoints. The company anticipates submitting a Biologics License Application (BLA) in the second half of 2025 and a Marketing Authorization Application (MAA) to the EMA in the first half of 2026.
• VRDN-003 (TED): A subcutaneous candidate currently in Phase 3 (REVEAL-1 and REVEAL-2). Topline data is expected in the first half of 2026, with a BLA submission anticipated by the end of 2026.
• FcRn Inhibitors: VRDN-006 received FDA IND clearance in January 2025, with proof-of-concept data expected in Q3 2025. VRDN-008 IND submission is targeted for the end of 2025.

Liquidity and Outlook

Management expects current cash and short-term investments ($717.6 million) to fund operations into the second half of 2027. The company has access to additional undrawn funds under its Hercules Loan and Security Agreement. The interest-only period on the Hercules loan was extended to April 1, 2026, following the achievement of clinical milestones.

Risks and Contingencies

• Manufacturing Reliance: The company relies on a single Chinese CDMO, WuXi Biologics, for clinical manufacturing. Geopolitical tensions and potential U.S. legislation (e.g., the BIOSECURE Act) pose risks to the supply chain.
• Capital Requirements: Continued significant losses are anticipated. Failure to raise additional capital could force delays in development or commercialization.
• Regulatory Uncertainty: Approval is not guaranteed, and regulatory authorities may require additional data or trials beyond current plans.

Key Facts for Investor Verification

• Cash Runway: Verify the company's projection that $717.6 million in liquidity is sufficient to fund operations through the second half of 2027, considering the high burn rate of ~$270 million annually.
• Manufacturing Supply Chain: Assess the specific mitigation strategies for reliance on WuXi Biologics in light of U.S. legislative proposals targeting Chinese biotechnology entities.
• BLA Submission Timeline: Monitor the progress of the veligrotug BLA submission scheduled for H2 2025, as this is the primary catalyst for potential revenue generation.
• Debt Covenants: Review the terms of the Hercules Loan and Security Agreement, specifically the covenants and the maturity date of October 1, 2026, to understand refinancing needs.
• Restatement Impact: Confirm that the correction to the net loss per share calculation does not indicate broader issues with financial reporting controls.